Cached evidence · two-stage review
Diligence candidates and evidence gaps
Zero fully qualified does not mean nothing interesting exists. Stage A asks what deserves further investigation. Stage B retains all four existing gates for an actionable thesis. Rights and commercial support remain separate from human evidence.
Current classification
877 trial–asset observations, not distinct purchasable assets.
QUALIFIED = existing gates supported under scoped assumptions, not a buy recommendation. PROMISING BUT INCOMPLETE = a sourced favorable human assessment without a recorded fatal flaw or concern; unresolved rights do not hide it. WATCH = a source or concern to investigate, not positive efficacy. UNQUALIFIED = a scoped fatal assessment, never simply missing information. CONFLICTED requires a confirmed scoped contradiction. UNKNOWN = no basis yet for prioritization.
38 observations have cached human-treatment links eligible for review. Publication count is not a scientific score. No clinical efficacy, safety or legal clearance follows from this count.
High-priority diligence
2 observations with scoped favorable human evidence under machine review. This is scientific diligence potential, not proof of investability or that a currently marketed treatment is an acquisition target. Missing ratings are not filled automatically. Inspect fully qualified opportunities.
PROMISING BUT INCOMPLETE · CURRENT RIGHTS: UNKNOWN · Commercial attractiveness: UNKNOWN
MACHINE REVIEW — Randomized open-label comparison supports relative remission maintenance in this AAV context; azathioprine was the comparator. This is not novel-asset availability, blanket safety or a new commercial opportunity.
Exact supporting sourceNext diligence question: Is there a differentiated, transferable product/indication opportunity beyond established clinical use? Obtain scoped rights instruments, contemporary treatment benchmarks and a supported market thesis before spending on a restart.
Cheap Truth: INCOMPLETE — 0/12 rated. No supportable capital/time-to-next-truth forecast or acquisition price.
PROMISING BUT INCOMPLETE · CURRENT RIGHTS: UNKNOWN · Commercial attractiveness: UNKNOWN
MACHINE REVIEW — Placebo comparison reports a renal composite benefit in the exact trial population. Established human efficacy is a reason to investigate a scoped hypothesis, not proof of rescue value, rights, market differentiation or current standard-of-care advantage.
Exact supporting sourceNext diligence question: Is there a differentiated, transferable product/indication opportunity beyond established clinical use? Obtain scoped rights instruments, contemporary treatment benchmarks and a supported market thesis before spending on a restart.
Cheap Truth: INCOMPLETE — 0/12 rated. No supportable capital/time-to-next-truth forecast or acquisition price.
High-value diligence queue
Up to 20 distinct asset labels from the 112 promising or Watch observations. Ordering favors scoped human support and interpretable treatment links, retains cautions, then considers exact trial linkage, available operational facts and freshness. Rights resolvability and Cheap Truth potential remain unknown. This is a transparent review priority, not an investment ranking. Publication volume does not affect ordering.
ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis
PROMISING BUT INCOMPLETE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:01.852803+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:02.195787+00:00. This check does not reconfirm current rights.
human_efficacy: SUPPORTS · MACHINE REVIEW — Randomized open-label comparison supports relative remission maintenance in this AAV context; azathioprine was the comparator. This is not novel-asset availability, blanket safety or a new commercial opportunity. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 21060104 — Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.Patients were randomly assigned to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after induction of remission with cyclophosphamide and prednisolone. A total of 156 patients were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for a median of 39 months (interquartile range, 0.66-53.6 months).
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextChronic Kidney Failure
PROMISING BUT INCOMPLETE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 1/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:02.596713+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:02.994532+00:00. This check does not reconfirm current rights.
human_efficacy: SUPPORTS · MACHINE REVIEW — Placebo comparison reports a renal composite benefit in the exact trial population. Established human efficacy is a reason to investigate a scoped hypothesis, not proof of rescue value, rights, market differentiation or current standard-of-care advantage. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 16407508 — Efficacy and safety of benazepril for advanced chronic renal insufficiency.After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextTriple Negative Breast Neoplasms
WATCH / NEEDS DILIGENCE · Human Signal REVIEW · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:03.359117+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:03.830096+00:00. This check does not reconfirm current rights.
human_efficacy: CONCERNS · MACHINE REVIEW — Negative primary comparison raises a scoped concern; both arms contain pembrolizumab, so this does not prove global pembrolizumab failure. Subgroup trends do not repair the primary result. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 41405563 — KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.Treatment-related adverse events occurred in 84.4% and 96.2% of participants receiving pembrolizumab plus olaparib and pembrolizumab plus chemotherapy, respectively.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextLymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:04.200183+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:04.618221+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 29141948 — A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.Patients were treated with pralatrexate (10 to 25 mg/m2) and romidepsin (12 to 14 mg/m2) on 1 of 3 schedules: every week × 3 every 28 days, every week × 2 every 21 days, and every other week every 28 days.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextPemphigus Vulgaris
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:04.939803+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:05.408419+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 18209165 — Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.Of the 9 patients receiving dapsone, 5 were successfully treated, 3 failed treatment, and 1 dropped out of the study. We found that, overall, 8 of 11 patients (73%) receiving dapsone vs 3 of 10 (30%) receiving placebo reached the primary outcome of a prednisone dosage of 7.5 mg/d or less.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextMultiple System Atrophy, Progressive Supranuclear Palsy
WATCH / NEEDS DILIGENCE · Human Signal REVIEW · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:05.758435+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:06.202297+00:00. This check does not reconfirm current rights.
human_efficacy: CONCERNS · MACHINE REVIEW — Large controlled negative result is a strong scoped concern. The old fatal conjunction additionally requires exposure/target-engagement adjudication not established here; no global molecule failure is invented. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 19029129 — Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.Patients were randomized to riluzole or matched placebo daily and followed up to 36 months.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextSchizophrenia
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:06.549631+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:06.965263+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42322923 — Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.Patients treated with amisulpride showed greater anti-inflammatory changes in cytokine serum levels than those treated with aripiprazole or olanzapine.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextMalaria, Falciparum
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:45.660891+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:45.996352+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42219079 — Day-7 lumefantrine exposure following artemether-lumefantrine treatment under routine outpatient conditions in a high-transmission Mozambican setting.This study evaluated day-7 lumefantrine concentrations among adults treated with artemether-lumefantrine for uncomplicated malaria under routine outpatient conditions in Mozambique and assessed the proportion of patients achieving pharmacokinetic thresholds associated with adequate therapeutic exposure.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextCarcinoma, Hepatocellular
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:46.350873+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:46.799017+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42485143 — Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort.A total of 368 patients were included [median age 74 years (interquartile range: 68-80 years); 303 (82%) male]; 307 (83.4%) received atezolizumab plus bevacizumab and 61 (16.6%) durvalumab plus tremelimumab.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextMetastatic Colorectal Cancer
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:47.165030+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:47.611900+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42272324 — Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study.Efforts to improve outcomes for patients with metastatic colorectal cancer (mCRC) treated with bevacizumab are limited by the lack of validated predictive biomarkers.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextAcute Pain Due to Trauma, Analgesia, Fentanyl, Esketamine, Emergency Medical Services
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:47.974195+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:48.408642+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42396903 — Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.In this single-center, double-blind, randomized trial, 84 patients scheduled for AN surgery were assigned to esketamine (n = 42) or placebo (n = 42).
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextSchizophrenia
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:06.549631+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:06.965263+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42636647 — Comparative effectiveness of olanzapine and risperidone on clinical outcomes of schizophrenia in a low-income country.A total of 1628 patients were included in the analysis, of whom 820 received risperidone and 808 received olanzapine. Extrapyramidal symptoms occurred more frequently among patients treated with risperidone than those treated with olanzapine (6.0%vs.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextSchizophrenia
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:06.549631+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:06.965263+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42551238 — Glymphatic system dysfunction in chronic schizophrenia: A comparison between risperidone combined with clozapine and risperidone monotherapy.This study compared glymphatic function between chronic schizophrenia patients receiving risperidone combined with clozapine (RCT-SZ) and risperidone monotherapy (RT-SZ), and explored its associations with clinical characteristics. Patients with schizophrenia treated with risperidone combined with clozapine exhibited a lower ALPS index than those receiving risperidone monotherapy, and the ALPS index was correlated with cognitive performance.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextMyelofibrosis
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:48.773075+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:49.201238+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42698151 — Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.This analysis suggests that patients treated with ruxolitinib and anemia-supporting care continued to receive optimal ruxolitinib dosing; spleen-length and symptom response rates in these patients were comparable to the overall JUMP population, the majority of whom did not have anemia.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextExtramedullary Disease in Multiple Myeloma, Multiple Myeloma
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 3/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:49.562323+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:50.191313+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 41483183 — Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.To evaluate costs per responder for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) receiving talquetamab (Tal) on weekly (QW) and biweekly (Q2W) dosing schedules, compared with usual care from a United States commercial payer's perspective.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextMalaria
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:50.530724+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:50.795656+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42114535 — Dihydroartemisinin-piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial.Between July 5, 2018, and Jan 13, 2021, 1649 patients were screened for eligibility, 419 of whom were randomly assigned to chloroquine plus primaquine (n=114), dihydroartemisinin-piperaquine plus primaquine (n=112), chloroquine plus delayed primaquine (n=98), and dihydroartemisinin-piperaquine plus delayed primaquine (n=95).
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextConscious Sedation
WATCH / NEEDS DILIGENCE · Human Signal REVIEW · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:51.142518+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:51.596620+00:00. This check does not reconfirm current rights.
human_efficacy: CONCERNS · MACHINE REVIEW — Randomized pilot, 85 patients: non-inferiority not confirmed and deep sedation target attainment lower. Post-hoc ventilation findings do not rescue the primary comparison. Concern applies to this ICU sedation trial; not all uses of dexmedetomidine. Adequate-failure/FATAL criteria not established. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42102350 — Choice of Anesthesia in Microelectrode Recording-guided Deep Brain Stimulation Surgery for Parkinson's Disease (CHAMPION): A Noninferiority Randomized Controlled Trial.During surgery, a desflurane anesthetic titrated against the quality of the electrophysiologic signal was applied in the general anesthesia group, whereas patients in the conscious sedation group received dexmedetomidine anesthesia.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextRenal Failure, Critically Ill
WATCH / NEEDS DILIGENCE · Human Signal REVIEW · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:51.920786+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:52.403086+00:00. This check does not reconfirm current rights.
human_efficacy: CONCERNS · MACHINE REVIEW — Randomized trial: physiological diuresis did not establish renal recovery benefit. 71 evaluable patients; renal recovery 25 vs 27, P=.46. Treat as a scoped efficacy concern, not evidence all furosemide uses fail or a sufficient FATAL finding. Supporting source
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42703448 — Association Between the Modified Furosemide Response Index and Prognosis in Patients with Chronic Kidney Disease: A Retrospective Cohort Study Based on the MIMIC-IV Database.Critically ill CKD patients receiving furosemide were included.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextCarcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:52.745299+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:53.192416+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 42541899 — Prophylactic folinic acid prevents pemetrexed myelosuppression: A randomized trial toward safer treatment with chemotherapy in non-small cell lung cancer.Methods Fifty patients treated with pemetrexed were randomized (1:1) to receive pemetrexed with or without oral folinic acid prophylaxis on days 2-4 after each chemotherapy cycle.
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry contextOveractive Bladder, Urinary Incontinence
WATCH / NEEDS DILIGENCE · Human Signal UNKNOWN · Current rights UNKNOWN · Market Pull UNKNOWN
Cheap Truth: INCOMPLETE — 0/12 reviewer-rated; 2/12 dimensions have source facts (not necessarily decision-sufficient).
Existing attributed human-treatment passage for inspection, not a positive efficacy conclusion.
Highest-value missing fact: Whether the exact product, treatment arm and indication support a clinically meaningful human effect with acceptable safety.
Source needed: Full trial results/CSR or primary human study with arm-level endpoints, exposure and adverse events; then scoped review.
Original cached PubMed assessment CACHED — partial context can remain even with a completed query. Other sources have not been revalidated by this page.
clinicaltrials: STALE · Exact registry record; posted results and trial status only. Last checked (UTC): 2026-09-21T20:09:53.571074+00:00. This check does not reconfirm current rights.
pubmed: STALE · Exact NCT search, first 20 hits; broader asset/alias evidence not covered. Last checked (UTC): 2026-09-21T20:09:53.973664+00:00. This check does not reconfirm current rights.
Inspect attributed source and exact blockers
Gate coverage remains incomplete; a scoped machine review is not a complete scientific, operational, rights or commercial assessment.
PMID 41852229 — Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: A single-arm retrospective study.Patients received tolterodine (4 mg/day) and duloxetine (40 mg twice daily).
AUTO_INFERRED treatment relationship; comparator/combination, indication and outcomes still require review.
Registry context